Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).

Status:
Completed

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

The aim of the study is to evaluate whether PF-04523655 is effective in the treatment of neovascular/wet AMD and at which dose.

Phase 2

Quark Pharmaceuticals

Pfizer

Ranibizumab